Willingness-to-pay for cancer treatment and outcome: a systematic review

Abstract

Background Understanding patient preferences in cancer management is essential for shared decision-making. Patient or societal willingness-to-pay (WTP) for desired outcomes in cancer management represents their preferences and values of these outcomes. Objective The aim of this systematic review is to critically evaluate how current literature has addressed WTP in relation to cancer treatment and achievement of outcomes. Methods Seven databases were searched from inception until 2 March 2021 to include studies with primary data of WTP values for cancer treatments or achievement of outcomes that were elicited using stated preference methods. Results Fifty-four studies were included in this review. All studies were published after year 2000 and more than 90% of the studies were conducted in high-income countries. Sample size of the studies ranged from 35 to 2040, with patient being the most studied population. There was a near even distribution between studies using contingent valuation and discrete choice experiment. Based on the included studies, the highest WTP values were for a quality-adjusted life year (QALY)

Willingness to Pay for a Quality-Adjusted Life Year among Gastrointestinal Cancer Patients at a Tertiary Hospital of Vietnam, 2022

“…In a similar study conducted among Malaysian population, the estimated value for the costeffectiveness threshold was $9,000 [23]. Furthermore, a meta-analysis of 54 studies evaluating WTP for cancer treatment and outcomes indicated that QALY exhibits the highest WTP ($11,498-$ 589,822) compared to 1-year survival, quality of life improvement, and pain reduction [24].…”

A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society

“…The per-capita GDP and WTP thresholds vary widely worldwide [ 22 , 23 ]. Our results suggest that adjunct capecitabine maintenance therapy could be treated as cost-effective when the per-capita GDP is above $876.7 (i.e., one-third of ICER), while only 24 out of 190 countries/regions (12.6%) are with per-capita GDP less than $876.7 [ 23 ].…”

A review of the cost-effectiveness of genetic testing for germline variants in familial cancer

“…31 This is an important area of research, especially in interventions for cancer patients, where there are uncertainties about WTP limits. [57][58][59][60] Future studies could provide valuable insight by weighing patient & stakeholder preferences for cost-utility of germline testing compared to other health care needs.…”